These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
877 related articles for article (PubMed ID: 11929822)
1. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Zhang L; Yu D; Hicklin DJ; Hannay JA; Ellis LM; Pollock RE Cancer Res; 2002 Apr; 62(7):2034-42. PubMed ID: 11929822 [TBL] [Abstract][Full Text] [Related]
2. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Kunkel P; Ulbricht U; Bohlen P; Brockmann MA; Fillbrandt R; Stavrou D; Westphal M; Lamszus K Cancer Res; 2001 Sep; 61(18):6624-8. PubMed ID: 11559524 [TBL] [Abstract][Full Text] [Related]
5. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Zhang L; Yu D; Hu M; Xiong S; Lang A; Ellis LM; Pollock RE Cancer Res; 2000 Jul; 60(13):3655-61. PubMed ID: 10910082 [TBL] [Abstract][Full Text] [Related]
6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
7. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704 [TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Zhang L; Hannay JA; Liu J; Das P; Zhan M; Nguyen T; Hicklin DJ; Yu D; Pollock RE; Lev D Cancer Res; 2006 Sep; 66(17):8770-8. PubMed ID: 16951193 [TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447 [TBL] [Abstract][Full Text] [Related]
15. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905 [TBL] [Abstract][Full Text] [Related]
16. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Klement G; Huang P; Mayer B; Green SK; Man S; Bohlen P; Hicklin D; Kerbel RS Clin Cancer Res; 2002 Jan; 8(1):221-32. PubMed ID: 11801563 [TBL] [Abstract][Full Text] [Related]
17. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Hess C; Vuong V; Hegyi I; Riesterer O; Wood J; Fabbro D; Glanzmann C; Bodis S; Pruschy M Br J Cancer; 2001 Dec; 85(12):2010-6. PubMed ID: 11747347 [TBL] [Abstract][Full Text] [Related]
18. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts. Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672 [TBL] [Abstract][Full Text] [Related]
19. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Shaheen RM; Tseng WW; Vellagas R; Liu W; Ahmad SA; Jung YD; Reinmuth N; Drazan KE; Bucana CD; Hicklin DJ; Ellis LM Int J Oncol; 2001 Feb; 18(2):221-6. PubMed ID: 11172585 [TBL] [Abstract][Full Text] [Related]
20. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]